<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545997</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.107</org_study_id>
    <nct_id>NCT03545997</nct_id>
  </id_info>
  <brief_title>Montelukast for Patients With Obstructive Sleep Apnea Syndrome</brief_title>
  <acronym>MONTSAS</acronym>
  <official_title>Impact of Blocked Cysteinyl Leukotriene Pathway on Endothelial Function in Patients With Obstructive Sleep Apnea Syndrome: Multicenter Randomized Placebo Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Act For Chronic Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of Montelukast vs Placebo on Flow Mediated Dilatation of the
      Brachial Artery (FMD) in patients with obstructive sleep apnea syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive Sleep Apnea Syndrome (OSAS) induces low-grade systemic and vascular inflammation,
      including activation of the leukotriene pathway.

      In apneic patients, the urinary excretion of LTE4, a systemic marker of CysLT pathway
      activation, is increased in relation to the severity of OSAS and it's an independent
      predictor of cardiovascular risk event occurring at 10 years.

      Montelukast is a CysLT1 receptor antagonist. By blocking CysLT1 receptors, montelukast
      prevents vasoconstriction, proliferation and migration of smooth muscle cells, adhesion
      molecule expression, and leukocyte recruitment induced by CysLTs.Montelukast may improve
      endothelial function and reduce vascular remodeling in apneic patients.

      A pharmacological blockade of CysLT pathway would be an interesting therapeutic strategy to
      limit the cardiovascular consequences of OSAS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>It's a prospective, randomized, comparative vs placebo, double blind, multicenter, national study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Montelukast will be crushed and coated in a capsule, Mannitol is into a capsule too.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FMD of the brachial artery between the beginning and end of each treatment period (Montelukast and placebo), expressed as absolute value (FMD unit is %) and measured in a standardized manner.</measure>
    <time_frame>before and after 3 months treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of urinary LTE4 at the beginning and end of each treatment period</measure>
    <time_frame>before and after 3 months the two periods of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h ambulatory blood pressure (systolic and diastolic) measurement</measure>
    <time_frame>before and after 3 months of the two periods of treatment, and 15 days after the last period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polysomnography at inclusion and at the end of each treatment period</measure>
    <time_frame>inclusion and at the end of the two periods of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Montelukast measured by HPLC-MS at the end of the Montelukast treatment period</measure>
    <time_frame>at the end of Montelukast treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events</measure>
    <time_frame>from inclusion to 15 days after the last period of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Cardiovascular Events occurence (myocardial infarction, Stroke, Cardiovascular Death) between the two periods</measure>
    <time_frame>from inclusion to 15 days after the last period of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of plasma CRPus at baseline and at the beginning and end of each treatment period</measure>
    <time_frame>before and after 3 months the two periods of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast 10mg</intervention_name>
    <description>The capsules will be presented in box of 95 capsules packaged in unit blister</description>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister</description>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With mild to moderate obstructive sleep apnea syndrome (apnea / hypopnea index&gt; 15 and
             &lt;30 events per hour)

          -  Little symptomatic (Epworth sleepiness score &lt;10)

          -  Polysomnography within 3 months prior to inclusion

          -  With a history of myocardial infarction or stroke

          -  Affiliation to Social Security or beneficiary of such a scheme

          -  Signed consent

        Exclusion Criteria:

          -  OSAS support by PPC

          -  Cancer

          -  Chronic inflammatory disease

          -  Asthma previously treated with Montelukast

          -  Chronic infectious disease

          -  Epworth sleepiness scale ≥10

          -  Contraindication to Montelukast: Hypersensitivity to the active substance or to the
             excipients

          -  Contraindications to trinitrin: hypersensitivity to nitrates, state of shock, severe
             hypotension, association with sildenafil, obstructive cardiomyopathy, inferior right
             sided myocardial infarction with right ventricular extension, acute, except in case of
             signs left ventricular failure, intracranial hypertension, breastfeeding

          -  Treatment with phenobarbital, phenytoin, rifampicin: risk of montelukast metabolism
             increase and thus decrease of its effectiveness

          -  Persons referred in Articles L1121-5 to L1121-8 of the CSP (pregnant woman,
             parturient, nursing mothers, person deprived of liberty by judicial or administrative
             decision, person subject to a measure of legal protection, can not be included in
             clinical trials)

          -  Subject in exclusion period of another study

          -  Subject can not be contacted in case of emergency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Françoise FS STANKE-LABESQUE, PhD</last_name>
    <phone>4 76 76 54 92</phone>
    <phone_ext>+33</phone_ext>
    <email>FStanke@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adeline AP PARIS</last_name>
    <phone>476767383</phone>
    <phone_ext>+33</phone_ext>
    <email>aparis@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia PF FRANCO</last_name>
      <phone>4 27 85 60 52</phone>
      <phone_ext>+33</phone_ext>
      <email>patricia.franco@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia PF FRANCO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Métropole Savoie Hospital</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric EK KELKEL, MD</last_name>
      <phone>4 79 96 50 86</phone>
      <phone_ext>+33</phone_ext>
      <email>Eric.Kelkel@ch-metropole-savoie.fr</email>
    </contact>
    <investigator>
      <last_name>Eric EK KELKEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia PB BEUDIN, PhD</last_name>
      <phone>4 73 75 16 66</phone>
      <phone_ext>+33</phone_ext>
      <email>pbeudin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia PB BEUDIN, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick AG GREIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise FS STANKE-LABESQUE, PhD</last_name>
      <phone>4 76 76 54 92</phone>
      <phone_ext>+33</phone_ext>
      <email>FStanke@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Adeline AP Paris, MD</last_name>
      <phone>476767383</phone>
      <phone_ext>+33</phone_ext>
      <email>AParis@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise FS STANKE-LABESQUE, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane SD Doutreleau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis JLP Pépin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Annecy Genevois Hospital</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toufik TD DIDI, MD</last_name>
      <phone>4 50 63 66 03</phone>
      <phone_ext>+33</phone_ext>
      <email>tdidi@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Toufik TD DIDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric FG GORMAND, MD</last_name>
      <phone>4 78 86 15 22</phone>
      <phone_ext>+33</phone_ext>
      <email>frederic.gormand@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric FG GORMAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric FR ROCHE, MD</last_name>
      <phone>4 77 82 83 00</phone>
      <phone_ext>+33</phone_ext>
      <email>frederic.roche@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric FR ROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012 Mar;129(3):702-707.e2. doi: 10.1016/j.jaci.2011.11.052. Epub 2012 Jan 12.</citation>
    <PMID>22244598</PMID>
  </reference>
  <reference>
    <citation>Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics. 2012 Sep;130(3):e575-80. doi: 10.1542/peds.2012-0310. Epub 2012 Aug 6.</citation>
    <PMID>22869829</PMID>
  </reference>
  <reference>
    <citation>Cereza G, Garcia Doladé N, Laporte JR. Nightmares induced by montelukast in children and adults. Eur Respir J. 2012 Dec;40(6):1574-5. doi: 10.1183/09031936.00092812.</citation>
    <PMID>23204025</PMID>
  </reference>
  <reference>
    <citation>Marchand M-S, Jonville-Béra A-P, Autret-Leca E. [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Arch pédiatrie organe Off la Sociéte Fr pédiatrie [Internet]. 2013 [cited 2016 Jun 14];20:269-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23375423</citation>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>leukotriene pathway</keyword>
  <keyword>endothelial function</keyword>
  <keyword>flux-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

